Letter to Congress Correcting False Claims About Bayh-Dale Act and § 1498 on Drug Price Controls

September 29, 2023

On September 28th, 2023, a letter was sent to the Senate Health, Education, Labor and Pensions Committee, the Chair and Ranking Member of the House Ways and Means Committee, and to Secretary Becerra correcting false claims that the federal government can use the Bayh-Dole Act or § 1498 to impose price controls on prescription drugs.

The letter is signed by 25 scholars, former judges, and former government officials, including Judge Paul Michel, Judge Randall Rader, Judge Kathleen O’Malley, Judge Susan Braden, the Honorable Andrei Iancu, the Honorable Walter Copan, and the Honorable Ronald Cass. It also includes leading scholars and patent and healthcare law experts, such as Jonathan Barnett, Richard Epstein, Emily Morris, Kristen Osenga, and Ted Sichelman, among many others.

Download the letter here: Letter to Congress – Bayh-Dole and 1498 Not Basis for Price Controls on Drug

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

February 5, 2026

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent

Universities, Patents, and the Future of U.S. Competitiveness

December 15, 2025

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties

How Counterfeit Drugs Threaten U.S. Health and Innovation

November 19, 2025

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor